

RESEARCH ARTICLE

WILEY

Factors influencing the performance of rapid SARS-CoV-2 antigen tests under field condition

Mst. Noorjahan Begum¹  | Mohammad Jubair¹ | Kamrun Nahar¹ | Sezanur Rahman¹  |
 Muhammad Talha¹ | Md Safiullah Sarker¹ | A K M Nasir Uddin² | Saifuddin Khaled² |
 Mohammed Shehab Uddin³ | Zhibiao Li⁴ | Tianlin Ke⁴ | Mohammed Ziaur Rahman¹ |
 Mustafizur Rahman¹ 

¹Virology Laboratory, Infectious Diseases Division, icddr, b: International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

²DNCC Dedicated Covid-19 Hospital, Dhaka, Bangladesh

³Kuwait Bangladesh Friendship Government Hospital, Dhaka, Bangladesh

⁴InTec PRODUCTS, INC, Fujian, China

Correspondence

Mustafizur Rahman, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
 E-mail: mustafizur@icddr.org

Funding information

InTec PRODUCTS, INC, Grant/Award Number: GR-02038

Abstract

Background: Globally, real-time reverse transcription-polymerase chain reaction (rRT-PCR) is the reference detection technique for SARS-CoV-2, which is expensive, time consuming, and requires trained laboratory personnel. Thus, a cost-effective, rapid antigen test is urgently needed. This study evaluated the performance of the rapid antigen tests (RATs) for SARS-CoV-2 compared with rRT-PCR, considering different influencing factors.

Methods: We enrolled a total of 214 symptomatic individuals with known COVID-19 status using rRT-PCR. We collected and tested paired nasopharyngeal (NP) and nasal swab (NS) specimens (collected from same individual) using rRT-PCR and RATs (InTec and SD Biosensor). We assessed the performance of RATs considering specimen types, viral load, the onset of symptoms, and presenting symptoms.

Results: We included 214 paired specimens (112 NP and 100 NS SARS-CoV-2 rRT-PCR positive) to the analysis. For NP specimens, the average sensitivity, specificity, and accuracy of the RATs were 87.5%, 98.6%, and 92.8%, respectively, when compared with rRT-PCR. While for NS, the overall kit performance was slightly lower than that of NP (sensitivity 79.0%, specificity 96.1%, and accuracy 88.3%). We observed a progressive decline in the performance of RATs with increased Ct values (decreased viral load). Moreover, the RAT sensitivity using NP specimens decreased over the time of the onset of symptoms.

Conclusion: The RATs showed strong performance under field conditions and fulfilled the minimum performance limit for rapid antigen detection kits recommended by World Health Organization. The best performance of the RATs can be achieved within the first week of the onset of symptoms with high viral load.

KEYWORDS

COVID-19 diagnosis, kit evaluation, Rapid antigen test, RAT, SARS-CoV-2

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Journal of Clinical Laboratory Analysis* published by Wiley Periodicals LLC.

1 | INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads rapidly worldwide, causing about 5 million deaths while writing this manuscript. During this prolonged COVID-19 pandemic, cost-effective rapid antigen tests (RATs) are warranted to detect SARS-CoV-2, especially in resource-limited settings. Currently, the real-time reverse transcription-polymerase chain reaction (rRT-PCR) is globally used and considered as the reference technique for detecting SARS-CoV-2 using nasopharyngeal (NP) swabs, throat swabs, nasal swab (NS), or saliva.¹⁻⁴ However, rRT-PCR requires highly trained laboratory personnel and well-equipped laboratory facilities. Therefore, in a resource-limited setting, specimens required transportation to a laboratory with rRT-PCR capability. This transportation, along with a time-consuming rRT-PCR procedure, delays in delivering test results and increases the anxiety of the suspected COVID-19 patients. Also, this delay in test result delivery increases the risk of SARS-CoV-2 transmission, especially in densely populated areas.⁵⁻⁷

The RAT using lateral flow principles have been introduced as quick and cost-effective methods to detect SARS-CoV-2 proteins. The most important feature of these test kits is that they can be used as point-of-care (POC) diagnostic tools that require neither trained laboratory personnel nor well-equipped laboratory facilities. These kits can increase the turn-around time for quick isolation of suspected cases in a remote and resource-limited area. Although the RAT is less sensitive than rRT-PCR, they can detect SARS-CoV-2 specimens of high viral load.⁷⁻¹² Therefore, several countries approved these kits for mass screening.¹³

Performance of RATs may vary depending on different influencing factors such as specimen type, quality of specimens, collection at the particular time point of disease progression, and viral load. For example, the sensitivity of SD Biosensor rapid SARS-CoV-2 antigen kits ranged from 75% to 98% in different settings.^{14,15} World Health Organization (WHO) recommended that a RAT should show at least 80% sensitivity with clinical specimens.¹⁶

Usually, NP specimens are recommended to detect respiratory viruses, including SARS-CoV-2, owing to their high sensitivity.¹⁷ However, obtaining NP specimens are difficult than NS and often requires trained personnel to avoid neck injury. In contrast, NS specimens can be collected more rapidly and efficiently; this technique can also be used for the self-sampling method. Previous studies showed that SARS-CoV-2 could be detected in NS specimens at an early stage of infection; however, viral load and sensitivity of NS have been a concern.¹⁸

The new RAT InTec Rapid SARS-CoV-2 Antigen Test (InTec PRODUCTS, INC., Fujian, P. R. China) was evaluated under field condition in Bangladesh. We compared the performance of this kit with the WHO recommended kit, Standard Q COVID-19 Ag (SD Biosensor, Korea), and gold standard rRT-PCR test.

2 | MATERIALS AND METHODS

2.1 | Study design and participant enrollment

A cross-sectional study of the diagnostic tests was designed to compare the performance of RATs with detect SARS-CoV-2 antigen. According to FDA, USA guideline, a minimum of 30 positive specimens and 30 negative specimens are required to evaluate each test.¹⁹ Accordingly, we enrolled 214 COVID-19 symptomatic participants who fulfilled WHO case definitions for COVID-19 and who had known rRT-PCR test results within the last 24 h, using NP swab. The criteria were as (i) all age group (ii) either sex; (iii) acute onset of fever or cough; OR (iv) acute onset of any three or more of the presented signs or symptoms, general weakness/fatigue, headache, myalgia, sore throat, runny nose, nasal congestion, dyspnea, anorexia/nausea/vomiting, diarrhea, and altered mental status.

2.2 | Ethical statements

This study protocol was approved by the Institutional Review Board of icddr,b (PR-20146). We obtained signed informed consent from all study participants before specimen and data collection, and followed standard biosafety and biosecurity protocols during sample collection and transportation. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

2.3 | Clinical specimen collection

During May-August 2021, we collected 214 paired NP and NS specimens in a 1-ml viral transport media (VTM) for rRT-PCR and SD Biosensor and 200- μ L buffer solution supplied with the InTec kit according to the manufacturer's instructions. We tested the specimens using rRT-PCR (following China CDC protocol), InTec (lot number: GJ21040477, Fujian, China), and SD Biosensor kits (lot number: QCO3020021C, Gyeonggi-do, South Korea), and the results were interpreted according to the manufacturers' guidelines.

2.4 | Rapid antigen test

Both InTec (Fujian, China) and SD Biosensor (Gyeonggi-do, South Korea) rapid tests use a lateral flow test format and are available as a cassette with a nitrocellulose strip containing control line (C) and test line (T). As per the InTec instructions, NP and NS specimens were collected and placed into the extraction buffer. Five drops of specimens were then dispensed in the 'specimen well' and observed the results in the 'result window' between 15 and 20 min. Finally, the test results were recorded based on the color

intensity of the band in the 'test line'. As for SD Biosensor, NP and NS specimens were collected and placed into VTM. Specimens in VTM, 350 μ L, was mixed with the extraction buffer supplied with the kit. Three drops of specimens were dispensed in the 'specimen well' and observed the results in the 'result window' between 15 and 30 min. Finally, the test results were recorded based on the color intensity of the band in the 'test line' by comparing them with a color-reference rating card.

2.5 | Real-time RT-PCR

We extracted total viral RNA from 200 μ L of each NP and NS specimen using the chemagic viral NA/gDNA kit (PerkinElmer, MA, USA) and tested the RNA for SARS-CoV-2 by rRT-PCR targeting ORF1ab (RdRp)-specific primers and probes following the protocol of the Chinese Center for Disease Control and Prevention (briefly as China CDC).²⁰ In brief, we prepared rRT-PCR reaction mixtures with iTaq™ Universal Probes and One-Step Reaction Mix (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and CFX96 Touch™ Real-time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used.²¹ We categorized all rRT-PCR-positive specimens as strong (Ct < 25), moderate (25–30), and weak (Ct > 30) positives.

2.6 | COVID-19 case definition

COVID-19 cases were defined as either one NP or NS was positive by RT-PCR.

2.7 | Statistical analysis

We calculated the sensitivity, specificity, and accuracy of the RATs with a 95% confidence interval (95% CI) using MedCalc online statistical software²² using the following formula:

Diagnostic sensitivity = $a/(a + c) \times 100$ (%) (95% CI), specificity = $d/(b + d) \times 100$ (%) (95% CI), and accuracy = $a + d / (a + b + c + d) \times 100$ (%) (95% CI), where a, true positive; b, false positive; c, false negative; and d, true negative. We analyzed data by Excel, SPSS version 21, EPI Info, and Graphpad prism9 software. We compared the influencing factors against the performance of RATs by chi-squared tests (95% CI).

3 | RESULTS

Among 214 participants, 118 were male, mean age was 40.6 years (range 0.5 to 95.0), and median was 38.0. We considered several factors such as specimen type, viral load, different disease stages (days of symptom onset), and presenting symptoms to evaluate the rapid kit performances. We documented major symptoms of COVID-19

when the participants submitted specimens. Fever was identified in 88% of the participants while coughing, 78%; muscle aches, 45%; sore throat, 28%; runny nose, 48%; shortness of breath, 21%; headache, 56%; loss of appetite, 14%; vomiting, 12%; nausea, 20%; joint aches, 17%; diarrhea, 17%; and altered smell, 27%.

3.1 | Specimen types

Among 214 study participants, a total of 112 NP or NS specimens were COVID-19 positive by rRT-PCR. Both NP and NS specimens were positive for 100 cases, 112 was positive for NP only, and 100 was positive for NS only.

3.1.1 | Nasopharyngeal swab specimen

Among 112 rRT-PCR-positive NP specimens, 102 (90.2%) and 95 (84.8%) were positive by InTec and SD Biosensor, respectively. All rRT-PCR negative (n = 102) remained negative using InTec rapid kits; however, all except 3 were negative using SD Biosensor. Thus, comparing with rRT-PCR results, the overall sensitivity of InTec for NP was 90.2% (95% CI, 83.1 to 95.0), the specificity was 100.0% (95% CI, 96.5 to 100.0), and the accuracy was 94.9% (95% CI, 91.0 to 97.4). The overall sensitivity of SD Biosensor was 84.8% (95% CI, 76.8 to 90.9), the specificity was 97.1% (95% CI, 91.6 to 99.4), and the accuracy was 90.7% (95% CI, 85.9 to 94.2) (Table 1). The average sensitivity, specificity, and accuracy of the two RATs were 87.5%, 98.6%, and 92.8%, respectively.

3.1.2 | Nasal swab specimens

Among 100 rRT-PCR-positive NS specimens, 80 (80%) and 78 (78%) were positive using InTec and SD Biosensor, respectively. Among 114 rRT-PCR-negative specimens, 3 and 6 were false positive using InTec and SD Biosensor, respectively. Thus, the overall sensitivity of InTec for NS was 80.0% (95% CI, 70.8 to 87.3), the specificity was 97.4% (95% CI, 92.5 to 99.5), and the accuracy was 89.6% (95% CI, 84.3 to 93.1) (Table 1). SD Biosensor kit showed the overall sensitivity was 78.0% (95% CI, 68.6 to 85.7), the specificity was 94.7% (95% CI, 88.9 to 98.0), and the accuracy was 86.9% (95% CI, 81.7 to 91.1). The average sensitivity, specificity, and accuracy of the two RATs were 79.0%, 96.1%, and 88.3%, respectively.

3.2 | Viral load (Ct value)

The NP specimens showed significantly low Ct values than NS specimens (mean 21.5, SEM 0.61, median 19.9, SD 6.5 vs. mean 25.0, SEM 0.58, median 24.6, SD 5.8; $p < 0.001$), and several NP-positive specimens resulted in negative for NS (Figure 1). For NP, among

TABLE 1 Nasopharyngeal and nasal swab: rapid antigen kits vs rRT-PCR (RdRp)

rRT-PCR	InTec Rapid SARS-CoV-2 Antigen Test					SD Biosensor Rapid SARS-CoV-2 Antigen Test						
	Positive	Negative	Positive	Negative	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy (95% CI)	Positive	Negative	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy (95% CI)
NP	Ct <25	86	NA	85	NA	98.8 (93.7 to 99.9)	NA	NA	84	NA	97.7 (91.9 to 99.7)	NA
	Ct 25–30	10	NA	8	NA	83.3 (51.6 to 97.9)	NA	NA	4	NA	62.5 (35.4 to 84.8)	NA
	Ct >30	16	NA	8	NA	50.0 (24.7 to 75.4)	NA	NA	7	NA	43.8 (19.8 to 70.1)	NA
	Overall	112	102	101	102	90.2 (83.1 to 95.0)	100.0 (96.5 to 100.00)	94.9 (91.0 to 97.4)	95	99	84.8 (76.8 to 90.9)	97.1 (91.6 to 99.4)
NS	Ct <25	55	NA	55	NA	100.0 (93.5 to 100.0)	NA	NA	54	NA	98.2 (90.3 to 99.9)	NA
	Ct 25–30	24	NA	19	NA	82.8 (64.2 to 94.2)	NA	NA	18	NA	80.0 (61.4 to 92.3)	NA
	Ct >30	21	NA	6	NA	28.6 (11.3 to 52.2)	NA	NA	6	NA	28.6 (11.3 to 52.2)	NA
	Overall	100	114	80	111	80.0 (70.8 to 87.3)	97.4 (92.5 to 99.5)	89.6 (84.3 to 93.1)	78	108	78.0 (68.6 to 85.7)	94.7 (88.9 to 98.0)
												86.9 (81.7 to 91.1)

Note: NA: Not applicable since negatives have no Ct values.

strong positives (Ct < 25), the sensitivity of InTec was 98.8% (95% CI, 93.7 to 99.9) and SD Biosensor was 97.7% (95% CI, 91.9 to 99.7). As for strong to moderate positives (Ct 25–30), the sensitivity of InTec and SD Biosensor was 83.3% (95% CI, 51.6 to 97.9) and 62.5% (95% CI, 35.4 to 84.8), respectively. The sensitivity for weak positive (Ct > 30) specimens was comparatively lower; 50.0% (95% CI, 24.7 to 75.4) using InTec and 43.8% (95% CI, 19.8 to 70.1) using SD Biosensor (Table 1).

NS also showed similar sensitivity pattern considering Ct values; for strong positive, the sensitivity of InTec and SD Biosensor was 100.0% (95% CI, 93.5 to 100.0) and 98.2% (95% CI, 90.3 to 99.9), while for moderate positive (Ct 25–30) specimens, the sensitivity of InTec and SD Biosensor was 82.8% (95% CI, 64.2 to 94.2) and 80.0% (95% CI, 61.4 to 92.3) (Table 1). The sensitivity of both RATs was much lower, 28.6% (95% CI, 11.3 to 52.2) for weak positives. In summary, we observed a progressive decline in the performance of RATs with the increased Ct values (Figure 1). In addition, we observed no remarkable difference in the performance of both RATs using NP and NS (Figure 2).

3.3 | Clinical consequences over the performance of RATs

We analyzed the performance of RATs using NP (112 positive and 102 negative) and NS (100 positive and 114 negative) specimens to evaluate clinical consequences over the performance.

3.3.1 | Onset of symptoms

We categorized the participants into three groups according to the onset of symptoms: 0–3 days (29, 13.6%), 4–7 days (117, 54.7%), and >7 days (68, 31.7%) (Table 2). Those who presented within 0–3 days were less likely to be positive than those between 4–7 days and >7 days using rRT-PCR. On the other hand, the sensitivity of InTec and SD Biosensor during 0–3 days was 100% compared with 96.6% vs. 89.8 during 4–7 days and 80.4% vs. 76.1% during >7 days using NP. As for NS, however, the highest sensitivity was observed for 4–7 days (Table 2).

3.3.2 | Symptoms

All study participants were symptomatic and presented different symptoms, as mentioned above. However, we did not find any significant association of symptoms with the sensitivity of the RATs (Supplementary Table ST1).

4 | DISCUSSION

In this study, we evaluated the performance of the SARS-CoV-2 RATs, considering different influencing factors. The RATs showed

strong performance in field conditions. Three major factors, ie, specimen types, viral load (Ct values), and the onset of symptoms, were identified as the influencing factors for the sensitivity of the RATs; however, we did not find any association of symptoms with the kit sensitivity.

The rRT-PCR quantitative values for NS were inconsistent, possibly due to uneven NS specimen collection. Therefore, both InTec and SD Biosensor RATs showed higher performance with NP specimens than NS specimens, which might be due to the low viral load in the NS specimen (relatively high Ct value). Moreover, in the early stage of COVID-19 infections, we found




FIGURE 1 Scatter dot plot for all specimens; X-axis denotes rRT-PCR Ct value for RdRp gene using nasopharyngeal swab specimen, and Y-axis denotes rRT-PCR Ct value for RdRp gene using nasal swab specimen

high viral load (low Ct value), resulting in increased sensitivity of NP specimens (100% sensitivity) than NS (71% sensitivity). Thus, considering the specimen type, NP was found more sensitive than NS.

We found that both RATs showed high performance (>90% sensitivity) for lower Ct values ($Ct \leq 30$). Previous studies showed that the rRT-PCR and other nucleic acid amplification tests (NAATs) were more sensitive than antigen tests to diagnose SARS-CoV-2,²³ which is inline with our findings where we found the relatively lower performance of RATs than rRT-PCR. However, the RATs (InTec and SD Biosensor) fulfilled the minimum performance limit for sensitivity (>80%) and specificity (>97%) set by WHO for the COVID-19 antigen test.¹⁶

Considering only symptomatic cases for enrollment was a limitation of this study as asymptomatic individuals could carry SARS-CoV-2 and act as the silent killer by accelerating viral spread in the community.²⁴⁻²⁶ Future studies should include asymptomatic populations and a more significant number of symptomatic cases with different times of symptom onset to observe the actual scenario. Also, rapid kit evaluation using a specimen from the asymptomatic individual will provide more confidence to use this kit for mass screening in entry points such as airports, educational institutes, and offices. However, the rapid kits are Ct value-dependent; thus, the kits will also be effective for asymptomatic cases.^{27,28} Another limitation of the study was evaluating the antigen test based on rRT-PCR results from clinical specimens, which missed more positive cases during the NS specimen test. Therefore, a virus culture assay would be helpful to identify the true positive cases for better evaluation of RATs.²⁹

In conclusion, the best performance of the RATs can be achieved with NP specimens within the first week of the onset of symptoms with high viral load. During this prolonged pandemic, the RATs can be applied to mass screening for SARS-CoV-2 including asymptomatic




FIGURE 2 Comparison of the rapid test result. (A) Box plot of rRT-PCR Ct value (positive only) compared with rapid test-positive and -negative result using a nasopharyngeal swab. (B) Box plot of rRT-PCR Ct value (positive only) compared with rapid test-positive and -negative result using a nasal swab

TABLE 2 Comparison of the rapid test based on the days of symptom onset and viral load using NP and NS specimens

Ct value	Test	NP						NS					
		0–3 days (n = 29)		4–7 days (n = 117)		>7 days (n = 68)		0–3 days (n = 29)		4–7 days (n = 117)		>7 days (n = 68)	
		Positive	Sensitivity	Positive	Sensitivity	Positive	Sensitivity	Positive	Sensitivity	Positive	Sensitivity	Positive	Sensitivity
<25	rRT-PCR	7		46		32		5		28		16	
	InTec	7	100	46	100	31	96.9	5	100	28	100	16	100
	SD Biosensor	7	100	46	100	31	96.9	5	100	28	100	16	100
25–30	rRT-PCR	0		5		6		1		17		14	
	InTec	0		5	100	4	66.7	0	0	15	88.2	12	85.7
	SD Biosensor	0		2	40.0	2	33.3	0	0	15	88.2	10	71.4
>30	rRT-PCR	0		8		8		1		8		10	
	InTec	0		6	75.0	2	25.0	0	0	2	25.0	2	20.0
	SD Biosensor	0		5	62.5	2	25.0	0	0	2	25.0	2	20.0
Overall	rRT-PCR	7		59		46		7		53		40	
	InTec	7	100	57	96.6	37	80.4	5	71.4	45	84.9	30	75.0
	SD Biosensor	7	100	53	89.8	35	76.1	5	71.4	45	84.9	28	70.0

individuals to reopen the office and educational institutes to limit the SARS-CoV-2 transmission.

ACKNOWLEDGMENTS

The InTec PRODUCTS INC. funded the study. icddr,b acknowledges with gratitude the commitment of the InTec PRODUCTS, INC. to its research efforts. icddr,b is also grateful to the Government of Bangladesh, Canada, Sweden, and the UK for providing core/unrestricted support.

CONFLICT OF INTEREST

MR received funding from InTec PRODUCTS, INC., for this work. ZL and TK are scientific staff of the InTec PRODUCTS, INC. but had no role in sample collection, laboratory evaluation, and analysis of this study. All other authors had no competing interests.

AUTHOR CONTRIBUTIONS

MR developed the protocol, methodology, conceived and coordinated the study, and reviewed the manuscript. MNB was involved in laboratory data interpretation, cleaned and finalized the dataset, performed the descriptive analyses, and prepared the first draft of the manuscript. MJ was involved in the analysis of laboratory data and provided intellectual input in the manuscript. KN built the questionnaires, collected clinical data for study participants, and supervised the specimen collection and recording. SR was involved in data analysis and intellectual input, and MT performed laboratory testing and provided intellectual information in data analysis. SS coordinated all the rapid tests in the field site. ANU, SK, and MSU were involved in study participant enrollment. ZL and TK critically reviewed the manuscript and provided intellectual input. MZR coordinated all the laboratory procedures and verified the data. All authors reviewed subsequent drafts of the manuscript and approved the final version.

DATA AVAILABILITY STATEMENT

All the data related to this work are available with the manuscript and supplementary file. All authors had full access to all the data in the study and accepted the responsibility to submit for publication.

ORCID

Mst. Noorjahan Begum  <https://orcid.org/0000-0001-7975-9383>

Sezanur Rahman  <https://orcid.org/0000-0002-0092-9261>

Mustafizur Rahman  <https://orcid.org/0000-0002-6876-0191>

REFERENCES

- Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *JAMA*. 2020;323(22):2249–2251.
- Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25(3):2000045.
- Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance [Internet]. World Health. 2020; [cited 21 March 2020]. Available from: <https://apps.who.int/iris/>

- bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdfhttps://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf [Internet].
4. [Internet]. Overview of Testing for SARS-CoV-2 (COVID-19). 2021;. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html
 5. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*. 2021;3.
 6. Yamayoshi S, Sakai-Tagawa Y, Koga M, et al. Comparison of rapid antigen tests for COVID-19. *Viruses*. 2020;12(12):1420.
 7. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. *Lancet Infect Dis*. 2021;21(9):e290-e295.
 8. GOV.UK. Liverpool COVID-19 community testing pilot: interim evaluation report summary. 2021
 9. Peto T, COVID U. COVID-19: rapid antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing. *medRxiv*. 2021;26
 10. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. *BMJ*. 2021;372:n208.
 11. Lee LY, Rozmanowski S, Pang M, et al. SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. *medRxiv*. 2021.
 12. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis*. 2021;21(5):629-636.
 13. Bruemmer LE, Katzenschlager S, Gaedert M, et al. The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. *medRxiv*. 2021.
 14. Chaimayo C, Kaewnaphan B, Tanlieng N, et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. *Viral J*. 2020;17(1):1-7.
 15. Rahman MM, Hoque AF, Karim Y, et al. Clinical evaluation of SARS-CoV-2 antigen-based rapid diagnostic test kit for detection of COVID-19 cases in Bangladesh. *Heliyon*. 2021;7(11):e08455.
 16. WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays.; 2020.Interim guidance 2020 World Health Organization
 17. Spencer S, Thompson MG, Flannery B, Fry A. Comparison of respiratory specimen collection methods for detection of influenza virus infection by reverse transcription-PCR: a literature review. *J Clin Microbiol*. 2019;57(9):e00027-e119.
 18. Kim HA, Hyun M, Lee JY, et al. Detection of SARS-CoV-2 in nasal swabs: Comparison with nasopharyngeal swabs. *J Infect Dev Ctries*. 2020;14(10):1081-1083.
 19. Food and Drug Administration. Policy for coronavirus disease-2019 tests during the public health emergency (revised) [Internet]. United States. 2020;. Available from: <https://www.hsdn.org/?view&did=838010>
 20. Niu P, Lu R, Zhao L, et al. Three novel real-time RT-PCR assays for detection of COVID-19 virus. *China CDC Wkly*. 2020;2(25):453.
 21. Das P, Satter SM, Ross AG, et al. A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh. *Trop Med Infect Dis*. 2021;6(2):41.
 22. Schoonjans F, Zalata A, Depuydt C, Comhaire F. Comhaire FJCM, biomedicine pi. MedCalc: a new computer program for medical statistics. *Comput Methods Programs Biomed*. 1995;48(3):257-262.
 23. Nucleic Acid Amplification Tests (NAATs) [Internet]. 2021 [cited June, 2021.]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/lab/naats.html>
 24. Dhama K, Khan S, Tiwari R, et al. Coronavirus disease 2019–COVID-19. *Clin Microbiol Rev*. 2020;33(4):e00028-e120.
 25. Machhi J, Herskovitz J, Senan AM, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. *J Neuroimmune Pharmacol*. 2020; 15(3):359-386.
 26. Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. *JAMA Intern Med*. 2020;180(11):1447-1452.
 27. Peña-Rodríguez M, Viera-Segura O, García-Chagollán M, et al. Performance evaluation of a lateral flow assay for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis. *J Clin Lab Anal*. 2021;35(5):e23745.
 28. Abusrewil Z, Alhudiri IM, Kaal HH, et al. Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays. *medRxiv*. 2021.
 29. Pickering S, Batra R, Merrick B, et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. *The Lancet Microbe*. 2021;2(9):e461-e471.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Begum MN, Jubair M, Nahar K, et al. Factors influencing the performance of rapid SARS-CoV-2 antigen tests under field condition. *J Clin Lab Anal*. 2022;36:e24203. doi:[10.1002/jcla.24203](https://doi.org/10.1002/jcla.24203)